Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Propranolol for Treatment of Cocaine Addiction - 2

This study has been completed.
Sponsor:
Collaborator:
University of Pennsylvania
Information provided by:
National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:
NCT00000197
First received: September 20, 1999
Last updated: February 3, 2010
Last verified: February 2010
  Purpose

The purpose of this study is to evaluate the safety and efficacy of propanolol in the early treatment of cocaine dependence.


Condition Intervention Phase
Cocaine-Related Disorders
Drug: Propranolol
Phase 2

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Propranolol for Treatment of Cocaine Addiction

Resource links provided by NLM:


Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • Side effects
  • Cocaine use
  • Cocaine withdrawal
  • Cocaine craving
  • Mood and anxiety
  • Clinical improvement

Estimated Enrollment: 0
Study Start Date: January 1987
Study Completion Date: January 2002
Primary Completion Date: January 2002 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   25 Years to 49 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Please contact site for information.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000197

Locations
United States, Pennsylvania
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104 6178
Sponsors and Collaborators
University of Pennsylvania
Investigators
Principal Investigator: Kyle Kampman, M.D. University of Pennsylvania
  More Information

No publications provided

Responsible Party: Kyle Kampman, University of Pennsylvania
ClinicalTrials.gov Identifier: NCT00000197     History of Changes
Other Study ID Numbers: NIDA-00238-2, K20DA000238
Study First Received: September 20, 1999
Last Updated: February 3, 2010
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Cocaine-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Substance-Related Disorders
Propranolol
Adrenergic Agents
Adrenergic Antagonists
Adrenergic beta-Antagonists
Anti-Arrhythmia Agents
Antihypertensive Agents
Cardiovascular Agents
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Vasodilator Agents

ClinicalTrials.gov processed this record on November 27, 2014